The company has not filed an annual or quarterly report since its Q2 FY2022 10-Q, filed Aug 5, 2022. Its latest SEC filing is a SC 13G/A from Feb 14, 2023.
10-Q for Q2 FY2022, filed Aug 5, 2022
The sections below describe the company as of the FY2021 annual report.
Develops drug candidates for patients with rare blood diseases and cancers, including sickle cell disease and prostate cancer.
10-K for FY2021, filed Mar 1, 2022
Large pharmaceutical companies work with Forma through collaboration agreements for research services, drug licenses and options for additional services.
10-K for FY2021, filed Mar 1, 2022
10-Q for Q2 FY2022, filed Aug 5, 2022
−$52.6MView ↗
8-K, filed Oct 14, 2022
On October 14, 2022, Forma (i) notified the Nasdaq Stock Market LLC (“Nasdaq”) of the consummation of the Merger and (ii) requested that…View ↗
8-K, filed Aug 5, 2022
On July 27, 2022 Forma entered into an exclusive worldwide license agreement with Rigel Pharmaceuticals, Inc. to develop, manufacture, and…View ↗
Competes with Bristol-Myers Squibb, Emmaus Life Sciences, Global Blood Therapeutics, Novartis, bluebird bio, CRISPR Therapeutics, Vertex Pharmaceuticals, Editas Medicine, Graphite Bio, Imara, Agios Pharmaceuticals, EpiDestiny, Novo Nordisk, Aruvant Sciences, Sangamo Therapeutics, Sanofi, Bellicum Pharmaceuticals, Orchard Therapeutics, Syros Pharmaceuticals, and CellCentric
10-K for FY2021, filed Mar 1, 2022Approved drug treatments for SCD focus primarily on the management of anemia and reduction of VOCs. Until November 2019, there were only…View ↗
Loading...
